Linking protein profiles to disease progression and clinical expression in Parkinson*s disease

Linking protein profiles to disease progression and clinical expression in Parkinson*s disease - Protein expression in Parkinson's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33857

Enrollment

282

Registered

2008-07-10

Start date

2008-09-11

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: PATIENTS (1) Patients of the outpatient clinic for movement disorders with a suspected parkinsonian syndrome, based upon the presence of at least one of the following parkinsonian symptoms: hypokinesia, bradykinesia, rigidity, tremor or postural instability. (2) Patients already under treatment at the outpatient clinic for movement disorders and diagnosed with PD or one of the following other parkinsonian syndromes: MSA, PSP, vascular parkinsonism. (3) Being able to understand the aim of the study and the study procedure and give written informed consent;HEALTHY CONTROLS Being able to understand the aim of the study and the study procedure and give written informed consent

Exclusion criteria

Exclusion criteria: PATIENTS (1) A history of neurological disorders other than a parkinsonian syndrome, that affect the central nervous system or are known to influence CSF proteins (2) Use of anticoagulants or indications for coagulation disorders (3) Infected skin over the needle entry side for lumbar puncture (4) Signs of raised intracranial pressure (5) Unwillingness to be informed of unexpected medical findings;HEALTHY CONTROLS (1) A history of neurological disorders that affect the central nervous system or are known to influence CSF proteins (2) Abnormal findings at general neurological examination (3) Use of anticoagulants or indications for coagulation disorders (4) Infected skin over the needle entry side for lumbar puncture (5) Signs of raised intracranial pressure (6) Unwillingness to be informed of unexpected medical findings

Design outcomes

Primary

Measure	Time frame
A lumbar puncture and a venous blood puncture will be performed in all patients and controls. For the subsequent analysis of CSF and serum samples, we will use a parallel approach. Previously discovered PD-related proteins will be validated in CSF and blood samples of PD patients, patients with parkinsonian symptoms not related to Parkinson*s disease and healthy controls using enzyme-linked immunosorbent assays (ELISAs) and Western Blotting. For the PD patients, we will analyze the association between CSF and serum proteins and clinical characteristics. In addition, we will perform state-of-the-art proteomics in order to discover new candidate biomarkers: proteins in CSF of eight early-stage PD patients, eight moderately advanced cases, eight advanced cases, and eight controls will be identified and quantified with stable isotope labelling (iTRAQ) in conjunction with multidimensional liquid chromatography coupled to tandem mass spectrometry. The newly discovered proteins will subsequently be validated in both CSF and blood samples of PD patients with various disease stages and clinical expression, patients with parkinsonian syndromes and control patients to evaluate the specificity of sensitivity of these potential biomarkers for PD, PD progression and PD phenotypes.	—

Measure

Time frame

A lumbar puncture and a venous blood puncture will be performed in all patients and controls. For the subsequent analysis of CSF and serum samples, we will use a parallel approach. Previously discovered PD-related proteins will be validated in CSF and blood samples of PD patients, patients with parkinsonian symptoms not related to Parkinson*s disease and healthy controls using enzyme-linked immunosorbent assays (ELISAs) and Western Blotting. For the PD patients, we will analyze the association between CSF and serum proteins and clinical characteristics. In addition, we will perform state-of-the-art proteomics in order to discover new candidate biomarkers: proteins in CSF of eight early-stage PD patients, eight moderately advanced cases, eight advanced cases, and eight controls will be identified and quantified with stable isotope labelling (iTRAQ) in conjunction with multidimensional liquid chromatography coupled to tandem mass spectrometry. The newly discovered proteins will subsequently be validated in both CSF and blood samples of PD patients with various disease stages and clinical expression, patients with parkinsonian syndromes and control patients to evaluate the specificity of sensitivity of these potential biomarkers for PD, PD progression and PD phenotypes.

—

Secondary

Measure	Time frame
not applicable.	—

Countries

Netherlands

Outcome results